| Business Summary | | Boston
Life
Sciences,
Inc.
is
a
development
stage
biotechnology
company
engaged
in
the
research
and
development
of
novel
therapeutic
and
diagnostic
products
to
treat
chronic
debilitating
diseases
such
as
cancer,
central
nervous
system
disorders
and
autoimmune
diseases.
With
the
exception
of
the
Altropane
imaging
agent,
all
of
the
Company's
technologies
and
early
stage
product
candidates
are
in
preclinical
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BLSI,
a
development
stage
biotechnology
company,
is
engaged
in
the
research
and
development
of
novel
therapeutic
and
diagnostic
products
to
treat
diseases
such
as
cancer,
central
nervous
system
disorders
and
autoimmune
diseases.
For
the
six
months
ended
6/30/01
the
Company
reported
no
revenues.
Net
loss
fell
15%
to
$5.4
million.
Results
reflect
lower
R&D
expenditures
for
the
Altropane
imaging
agent,
lower
interest
costs,
and
an
increase
in
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| S. David Hillson, 61 Chairman,
Pres, CEO | $410K | $587K | Joseph Hernon, 41 CFO
and Sec. | 215K | 135K | Marc Lanser, M.D., 52 Exec.
VP, CSO, Director | 265K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|